MA55614A - Formes cristallines d'inhibiteur de pyridazinone trpc - Google Patents

Formes cristallines d'inhibiteur de pyridazinone trpc

Info

Publication number
MA55614A
MA55614A MA055614A MA55614A MA55614A MA 55614 A MA55614 A MA 55614A MA 055614 A MA055614 A MA 055614A MA 55614 A MA55614 A MA 55614A MA 55614 A MA55614 A MA 55614A
Authority
MA
Morocco
Prior art keywords
trpc
pyridazinone
inhibitor
crystalline forms
crystalline
Prior art date
Application number
MA055614A
Other languages
English (en)
Inventor
Yuejun Gao
Wenfeng Xue
Original Assignee
Goldfinch Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldfinch Bio Inc filed Critical Goldfinch Bio Inc
Publication of MA55614A publication Critical patent/MA55614A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
MA055614A 2019-04-10 2020-04-10 Formes cristallines d'inhibiteur de pyridazinone trpc MA55614A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/081985 WO2020206623A1 (fr) 2019-04-10 2019-04-10 Formes cristallines

Publications (1)

Publication Number Publication Date
MA55614A true MA55614A (fr) 2022-02-16

Family

ID=70482847

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055614A MA55614A (fr) 2019-04-10 2020-04-10 Formes cristallines d'inhibiteur de pyridazinone trpc

Country Status (10)

Country Link
US (1) US20220177455A1 (fr)
EP (1) EP3953352A1 (fr)
JP (2) JP7738482B2 (fr)
CN (2) CN114502552B (fr)
AU (2) AU2020272030B2 (fr)
BR (1) BR112021018221A2 (fr)
CA (1) CA3136652A1 (fr)
MA (1) MA55614A (fr)
MX (2) MX2021012313A (fr)
WO (2) WO2020206623A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3075727A1 (fr) 2017-09-18 2019-03-21 Goldfinch Bio, Inc. Pyridazinones et leurs procedes d'utilisation
MD3852533T2 (ro) * 2018-09-18 2024-08-31 Gfb Abc Llc Piridazinone și metode de utilizare ale acestora
SG11202110585SA (en) * 2019-04-11 2021-10-28 Goldfinch Bio Inc Spray-dried formulation of a pyridazinone trpc5 inhibitor
AU2021302090B2 (en) * 2020-07-03 2024-01-18 Wuhan Ll Science And Technology Development Co., Ltd. Heterocyclic compound and use thereof
CN117940417A (zh) * 2021-09-10 2024-04-26 南京明德新药研发有限公司 卤素取代的哒嗪酮类化合物及其应用
US20250082655A1 (en) * 2022-01-27 2025-03-13 Wuhan Createrna Science And Technology Co., Ltd. Use of heterocyclic compound
WO2024027752A1 (fr) * 2022-08-05 2024-02-08 武汉朗来科技发展有限公司 Composition pharmaceutique comprenant un composé hétérocyclique, procédé de préparation associé et utilisation correspondante
WO2025250920A1 (fr) 2024-05-31 2025-12-04 Gfb (Abc), Llc Composés de pyridazinone phosphate, compositions pharmaceutiques et leurs utilisations médicales

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP310798A0 (en) * 1998-04-22 1998-05-14 Soltec Research Pty Ltd Vehicle system for a composition comprising a piperidinopyrimidine derivative
US8633233B2 (en) * 2008-08-06 2014-01-21 Hydra Biosciences, Inc. Methods and compositions for treating anxiety
EP3180340B1 (fr) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Dérivés de pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione
CA3075727A1 (fr) * 2017-09-18 2019-03-21 Goldfinch Bio, Inc. Pyridazinones et leurs procedes d'utilisation
MD3852533T2 (ro) 2018-09-18 2024-08-31 Gfb Abc Llc Piridazinone și metode de utilizare ale acestora

Also Published As

Publication number Publication date
AU2020272030B2 (en) 2025-11-13
JP7738482B2 (ja) 2025-09-12
BR112021018221A2 (pt) 2022-01-18
US20220177455A1 (en) 2022-06-09
CA3136652A1 (fr) 2020-10-15
CN119264134A (zh) 2025-01-07
JP2026004294A (ja) 2026-01-14
MX2025006384A (es) 2025-07-01
WO2020206623A1 (fr) 2020-10-15
CN114502552A (zh) 2022-05-13
JP2022525759A (ja) 2022-05-19
AU2026201003A1 (en) 2026-03-05
AU2020272030A1 (en) 2021-11-11
EP3953352A1 (fr) 2022-02-16
CN114502552B (zh) 2024-08-16
MX2021012313A (es) 2021-11-17
WO2020210639A1 (fr) 2020-10-15

Similar Documents

Publication Publication Date Title
MA55614A (fr) Formes cristallines d'inhibiteur de pyridazinone trpc
EP3870178A4 (fr) Formes cristallines d'inhibiteurs de mnk
EP3924352A4 (fr) Formes cristallines d'un inhibiteur rsk
MA53226A (fr) Sel et formes cristallines d'omecamtiv mecarbil
DK4045039T3 (da) Hæmning af human integrin-alfa4beta7
EP3870181A4 (fr) Formes cristallines d'un inhibiteur d'alk2
IL286218A (en) Solid state forms of ripretinib
EP3947361A4 (fr) Sel et forme cristalline d'un inhibiteur de fak
DK4058453T3 (da) Forbedret syntese af kras g12c-inhibitorforbindelse
MA54458A (fr) Formes cristallines et formes salines d'un inhibiteur de kinase
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
EP3619208C0 (fr) Formes cristallines d'un composé inhibiteur de jak
EP3786157A4 (fr) Inhibiteur de l'interaction protéine-protéine mll1-wdr5 de phényle triazole
MA56001A (fr) Formes de sel cristallin d'un inhibiteur de kinase
DK3999038T3 (da) Orale formuleringer af en kardial sarcomer-inhibitor
EP4337203A4 (fr) Inhibiteurs de l'interaction ménine-mll
EP3807279A4 (fr) Sels pharmaceutiquement acceptables de sépiaptérine
EP3782987A4 (fr) Composé de benzo-pyrazole tenant lieu d'inhibiteur de la rho-kinase
EP3866780C0 (fr) Dérivés de flavagline pour inhiber l'activation de l'oncogène kras
MA55801A (fr) Formes solides d'un inhibiteur de glyt1
IL289111A (en) Uridine phosphorylase (upase) inhibitors for treatment of liver conditions
MA54689A (fr) Formes cristallines de 1-(1,2-diméthylpropyl)-n-éthyl-5-méthyl-n-pyridazin-4-yl-pyrazole-4-carboxamide
EP3954683A4 (fr) Promédicament d'inhibiteur de caspase
EP3996707A4 (fr) Formes cristallines d'inhibiteurs de la kallicréine plasmatique
EP3897660A4 (fr) Nouvelles formes cristallines d'un composé de nrtti